Non-adherence to the treatment regimen is a common problem associated with injectable drugs (e.g. Betaferon) that are used in multiple sclerosis patients. Certain patients omit single injections or even totally discontinue therapy that normally should be long-term. It is therefore crucial to identify the factors which have the most significant effect on regularity of administration of Betaferon and the risk of premature discontinuation of treatment in order to undertake appropriate preventive measures. This study is conducted in routine practice setting and aims to identify those risks. Pre-defined risk factors associated with technical aspects of the treatment, support provided to the patient, stage of the disease and possible adverse effects of the medication are checked on a quarterly basis with a questionnaire method. Monitoring of omitted doses of the prescribed medication (Betaferon) is carried out by the study nurse.
Study Type
OBSERVATIONAL
Enrollment
852
Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
Unnamed facility
Many Locations, Poland
Rate of discontinuation of Betaferon
Time frame: 24 months
Number of missed doses of Betaferon
Time frame: 24 months
Depression score as measured by CES-D questionnaire
Time frame: 24 months
Neurological disability score as measured by EDSS scale
Time frame: 24 months
Overall tolerability of treatment as measured by rate of adverse events
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.